Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 36 Neoplasm Metastasis 10 Neoplasms 7 Brain Neoplasms 4 Triple Negative Breast Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Advanced Malignant Solid Tumors 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Lung Neoplasms 2 Colorectal Neoplasms 2 Uterine Cervical Neoplasms 1 Thrombocytosis 1 Solid Tumor 1 Salivary Gland Neoplasms 1 Recurrence 1 Rare Tumour 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Neuroma, Acoustic 1 Neurofibromatosis 2 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Multiple Myeloma 1 Meningioma 1 Malignant Female Reproductive System Neoplasm 1

Interventions

Fulvestrant 19 Letrozole 8 Anastrozole 6 Capecitabine 5 palbociclib 4 olaparib 4 Paclitaxel 4 Injections 4 Goserelin 4 Docetaxel 4 pyrotinib 3 exemestane 3 trastuzumab deruxtecan 2 toripalimab 2 sacituzumab govitecan 2 ribociclib 2 eribulin 2 elacestrant 2 abemaciclib 2 Vinorelbine 2 Trastuzumab 2 FCN-437c 2 Everolimus 2 Dasatinib 2 Aromatase Inhibitors 2 Alpelisib 2 Albumin-Bound Paclitaxel 2 AZD9833 2 vandetanib 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Advanced Breast Cancer × neratinib × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡